SPTX
HealthcareSeaport Therapeutics, Inc. Common Stock
Key Drivers
- Cash Cushion
- No Revenue
- Negative Equity
AIAI Summary
SPTX has shifted from a near-term survival story to a catalyst-driven biotech with enough cash to fund operations into 2029, but the stock's upside now hinges on whether early Phase 1 promise converts into patient-level efficacy in Phase 2b before the market begins to discount the runway and recent gains.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •No Revenue
- •Negative Equity
SPTX has ample liquidity and minimal debt, but the complete lack of revenue, persistent cash burn, and deeply negative equity make it financially risky despite its cash cushion.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Momentum cooled
- •Support holding
SPTX has trended higher over the last month, but three straight declines from the late-June high show near-term momentum has cooled even as support around $19.30-$19.40 still holds.
Three straight declines from the $22.52 late-June high suggest short-term profit-taking
Sentiment & News
Key News Insights:
- •Q1 Progress
- •Positive GlyphAgo Data
- •Clinical Momentum
Seaport Therapeutics reported solid Q1 2026 progress and encouraging positive Phase 1 GlyphAgo™ data, reinforcing early clinical momentum in its pipeline.
This is a positive signal for the instrument, as early-stage clinical success and steady execution may improve investor confidence in the pipeline
Similar Companies in Healthcare
Other companies in the same sector with AI ratings